Abstract: The present invention features biarsenical molecules. Target sequences that specifically react with the biarsenical molecules are also included. The present invention also features kits that include biarsenical molecules and target sequences. Tetraarsenical molecules are also featured in the invention.
Type:
Grant
Filed:
April 19, 2002
Date of Patent:
February 3, 2004
Assignee:
The Regents of the University of California
Abstract: A muscarinic acetylcholine nervous system labeled compound for positron emission tomography measurement of the present invention has a structure represented by undermentioned general formula (I):
[in the formula, W represents one selected from the group consisting of groups represented by undermentioned formulae (II) and (III):
(in the formulae, R represents one selected from the group consisting of an 11C-labeled ethyl group and an 11C-labeled propyl group), and in the case that W is a group represented by above-mentioned formula (II), above-mentioned formula (I) is the (+)-isomer].
Abstract: The present invention provides basic ionic contrast agents that have anticoagulant activity. The contrast media incorporate a lysine or arginine group or derivative, and have a free amino or guanidino group. Methods of using the contrast media are also disclosed.
Type:
Grant
Filed:
September 27, 2002
Date of Patent:
August 26, 2003
Assignee:
The University of North Carolina at Chapel Hill
Abstract: The present invention provides pharmaceutically active compounds useful for the treatment of diseases or disorders of the central nervous system.
Type:
Grant
Filed:
October 2, 2001
Date of Patent:
July 1, 2003
Assignee:
Pharmacia & Upjohn Company
Inventors:
Eric Jon Jacobsen, Stephen J. King, Kalpana M. Merchant
Abstract: The present invention relates to N-alkylpiperidine derivatives represented by general formula (1) or (2);
wherein R1 represents optionally fluorinated lower alkyl; R2 represents lower alkyl; and R3 represents alkenyl substituted at the 1-position with hydroxy, lower alkoxy, lower alkoxyalkyloxy, lower alkoxyalkyloxyalkyloxy, or lower alkanoyloxy and substituted at the end with radioactive iodine, or alkenyloxymethyl substituted at the end with a radioactive iodine reagent containing the same for assaying central local AchE activity; a method for assaying the central local AchE activity; and labeled precursors of the above compounds. After easily passing through the blood-brain barrier, these compounds are hydrolyzed specifically by AchE in the brain into alcohols, which are then captured by the brain. In contrast, alcohols formed outside the brain do not migrate into the brain. The compounds of the invention emit &ggr;-rays at an appropriate energy level.
Type:
Grant
Filed:
January 19, 2001
Date of Patent:
January 21, 2003
Assignees:
Daiichi Pure Chemicals Co., Ltd., Daiichi Radioisotope Laboratories, Ltd.
Abstract: A compound comprising a ligand portion which has binding affinity for an opioid receptor, and a therapeutically or diagnostically effective group selected from radionuclide chelating agents, fluorochromes, toxins, drugs, polyboron moieties, proteins, biological response modifiers, chemical moieties capable of binding to other molecules of interest, and radioisotopes selected from therapeutically effective alpha and beta emitters, and diagnostically effective gamma emitters. The compound may be used in a method of treating cancer, and in a method of imaging opioid receptors either inside or outside of the central nervous system.
Abstract: The properties of a tissue extracellular space, particularly the microvascular component of that space can be characterized by the use of x-ray diagnostic modalities in conjunction with particulate contrast agents. The present invention provides a method for characterizing a property of a tissue extravascular space utilizing radiopaque particulate contrast. Moreover, the present invention provides a novel class of particulate agents suitable for use in conjunction with the methods provided herein.
Type:
Grant
Filed:
December 8, 1998
Date of Patent:
March 20, 2001
Assignee:
The Regents of the University of California